CRIS Current Research Information System

LANDUZZI, LORENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.034
AS - Asia 4.732
EU - Europa 3.500
AF - Africa 295
SA - Sud America 211
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.779
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.945
VN - Vietnam 1.724
CN - Cina 1.102
SG - Singapore 1.074
IT - Italia 935
GB - Regno Unito 663
DE - Germania 467
HK - Hong Kong 309
SE - Svezia 288
FR - Francia 200
IN - India 167
RU - Federazione Russa 163
BR - Brasile 152
NL - Olanda 140
CH - Svizzera 124
UA - Ucraina 119
IE - Irlanda 110
CI - Costa d'Avorio 106
ZA - Sudafrica 76
FI - Finlandia 68
KR - Corea 67
CA - Canada 66
JP - Giappone 65
TG - Togo 57
EE - Estonia 45
BG - Bulgaria 39
BE - Belgio 30
ID - Indonesia 30
PH - Filippine 28
JO - Giordania 25
TR - Turchia 24
PL - Polonia 23
AR - Argentina 21
TH - Thailandia 21
MX - Messico 17
BD - Bangladesh 15
RO - Romania 14
SC - Seychelles 14
LT - Lituania 13
AT - Austria 12
EC - Ecuador 12
IQ - Iraq 12
NG - Nigeria 12
PK - Pakistan 12
TW - Taiwan 12
EG - Egitto 11
CL - Cile 8
GR - Grecia 8
CO - Colombia 7
HR - Croazia 7
IR - Iran 7
SA - Arabia Saudita 7
ES - Italia 6
MA - Marocco 6
KE - Kenya 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
DK - Danimarca 4
MD - Moldavia 4
AL - Albania 3
AZ - Azerbaigian 3
MY - Malesia 3
PT - Portogallo 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BO - Bolivia 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HU - Ungheria 2
KG - Kirghizistan 2
KH - Cambogia 2
LB - Libano 2
LV - Lettonia 2
PE - Perù 2
PS - Palestinian Territory 2
PY - Paraguay 2
UY - Uruguay 2
YE - Yemen 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AO - Angola 1
BJ - Benin 1
BW - Botswana 1
ET - Etiopia 1
GE - Georgia 1
HN - Honduras 1
IL - Israele 1
JM - Giamaica 1
KZ - Kazakistan 1
LI - Liechtenstein 1
MK - Macedonia 1
MN - Mongolia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
SI - Slovenia 1
SN - Senegal 1
Totale 13.777
Salva come PNG Salva come JPEG
Città #
Singapore 758
Ashburn 539
Southend 526
Fairfield 512
Chandler 481
Ho Chi Minh City 372
Hanoi 342
Hong Kong 298
Ann Arbor 240
Woodbridge 237
Bologna 224
Houston 222
San Jose 208
Seattle 208
Wilmington 206
Dong Ket 198
Shanghai 177
Cambridge 166
Santa Clara 149
Hefei 148
Princeton 133
Beijing 114
Bern 112
Dublin 110
Abidjan 106
Boardman 102
Frankfurt am Main 95
Lauterbourg 78
Jacksonville 75
Council Bluffs 70
Dallas 63
Lomé 57
Nanjing 56
Los Angeles 55
Tokyo 55
Seoul 54
Westminster 53
Bremen 52
Helsinki 49
Milan 49
Haiphong 46
Padova 45
Berlin 43
Da Nang 43
Sofia 39
Guangzhou 38
Buffalo 35
New York 33
San Diego 32
Jinan 31
Shenyang 30
Brussels 29
London 28
Amsterdam 27
Turin 27
Saint Petersburg 26
Amman 25
Des Moines 25
Phoenix 25
Redondo Beach 25
Falkenstein 24
Jakarta 24
Johannesburg 24
Ottawa 24
Redmond 24
Hải Dương 23
Redwood City 23
Can Tho 22
Casalecchio di Reno 22
Biên Hòa 21
Hebei 19
Nanchang 19
Changsha 18
São Paulo 17
Toronto 17
Warsaw 17
Ha Long 16
Mülheim 16
Tianjin 16
Quận Bình Thạnh 15
Atlanta 14
Bengaluru 13
Florence 13
Lappeenranta 13
Quận Ba 13
Yubileyny 13
Jiaxing 12
Montreal 12
San Giovanni in Persiceto 12
Verona 12
Zhengzhou 12
Parma 11
Abeokuta 10
Bühl 10
Bắc Ninh 10
Moscow 10
Ninh Bình 10
Nuremberg 10
Paris 10
San Francisco 10
Totale 9.032
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 429
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 383
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity 374
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 339
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 321
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 281
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 267
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 249
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 246
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscape 237
Virus-like particle display of HER2 induces potent anti-cancer responses 232
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 228
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 227
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 219
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 213
CD99 Acts as an Oncosuppressor in Osteosarcoma. 212
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 212
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 211
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 210
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma 204
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. 203
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 202
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 201
In silico modeling and in vivo efficacy of cancer preventive vaccinations 199
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 198
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 196
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 195
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 194
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 192
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 191
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 187
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 187
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 187
Targeting CD99 compromises the oncogenic effects of the chimera EWS-FLI1 by inducing re-expression of zyxin and inhibition of Gli1 activity 187
Antimetastatic activity of a preventive cancer vaccine. 186
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research 185
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 185
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 182
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 179
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality 178
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 178
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 178
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer 177
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 176
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 174
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 173
Immunoprevention and immunotherapy of mammary carcinoma 172
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 167
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 165
Immunological prevention of a multigene cancer syndrome 164
TRAF6 regulates proliferation and differentiation of skeletal myoblasts 161
NVE-BEZ235 as a new therapeutic option for sarcomas. 161
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 160
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 159
Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma 157
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. 157
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 151
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 150
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 149
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 149
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma 149
RIP2 regulates growth and differentiation of normal myoblasts and of rhabdomyosarcoma cells. 146
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 146
APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. 145
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 145
Molecular and cellular biology of rhabdomyosarcoma 143
Vaccines and other immunological approaches for cancer immunoprevention 135
Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma 134
Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma. 126
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 125
Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. 124
IL-1 Family Members in Bone Sarcomas 112
Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts 65
Totale 14.081
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.793
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.793
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021457 0 0 0 0 0 0 0 0 0 0 49 408
2021/20221.471 122 48 104 58 123 86 39 107 81 128 337 238
2022/20231.923 183 227 111 277 123 132 67 104 278 73 176 172
2023/2024630 28 80 28 47 38 63 36 221 17 32 13 27
2024/20251.926 135 246 154 114 282 115 132 88 20 156 98 386
2025/20264.550 762 439 345 327 489 210 422 157 913 380 106 0
Totale 14.081